GeoPark (NYSE: GPRK ) presents itself today as a company that knows exactly what it wants to focus on: profitability, discipline and sustainable value creation. With a valuation that remains highly attractive and an oiled operation, it prioritizes the return of capital Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not refle ...

Umicore upgrades guidance Following a strong start in Q1 2025, performance continued to be very solid throughout the first half of the year. In this context and based on the information available to date, Umicore expects H1 Group adjusted EBITDA to come in somewhat above €420 million. This primarily reflects: Stronger-than-anticipated performance of the Catalysis Business Group.A supportive metal price environment, particularly for minor and specialty metals, along with a favorable trading environment in th ...

Transparency notification byBlackRock, Inc. In accordance with article 14, § 1 of the law of 2 May 2007 on the disclosure of major holdings, Umicore was recently notified by BlackRock, Inc. that it has crossed the legal threshold of 3% for the direct voting rights downwards on 11 June 2025. The total holding of direct voting rights and equivalent financial instruments of BlackRock, Inc. stands at 4.46% on 11 June 2025. Summary of the move: Date on which the threshold was crossedDate of notificationDirect vo ...

Transparency notifications byBlackRock, Inc. In accordance with article 14, § 1 of the law of 2 May 2007 on the disclosure of major holdings, Umicore was recently notified by BlackRock, Inc. that it has successively crossed the legal threshold of 3% for the direct voting rights downwards on 5 June 2025 and then upwards on 10 June 2025. The total holding of direct voting rights and equivalent financial instruments of BlackRock, Inc. stands at 4.53% on 10 June 2025. Summary of the moves: Date on which the thr ...

CALGARY, AB, May 29, 2025 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that its Canna Cabana retail cannabis store located at 2020 Sherwood Drive in Sherwood Park, Alberta, will begin selling recreational cannabis products and consumption accessories for adult use on June 3, 2025. This opening brings High Tide's total store ...

Summary of BridgeBio Pharma (BBIO) 2025 Conference Call Company Overview - **Company**: BridgeBio Pharma - **Event**: 2025 Bank of America Healthcare Conference - **Date**: May 14, 2025 Key Points Industry and Company Strategy - BridgeBio's objective is to create patient impact through sustainable value creation, focusing on delivering benefits to patients in the shortest time possible [2][3] - The company employs a decentralized operating model, enhancing efficiency and focus, leading to outperformance against industry benchmarks [3][4] - The biopharma industry is likened to a lottery, necessitating a broad portfolio approach to mitigate risks associated with R&D projects [4] Product Pipeline and Market Opportunities - The late-stage pipeline includes promising products like Atruby, with significant upcoming phase three readouts for achondroplasia, ADH1, and girdle 2i [5] - Atruby, a stabilizer for ATTRCM, reported first-quarter revenues of $37 million, exceeding internal expectations [6][9] - The peak market potential for Atruby is estimated at $15.8 billion, indicating a larger market opportunity than currently recognized [9] Commercial Launch and Performance - The commercial organization under Matt Alton is highlighted as a key factor in the successful launch of Atruby, with strong early momentum and demand [6][7] - Clinical data shows a 42% reduction in composite outcome events and a 50% reduction in hospitalizations, enhancing the drug's appeal [8][9] - The company is focused on driving market share in the frontline treatment naive pool, which is crucial for long-term value [11] Competitive Landscape and Growth Drivers - The market for ATTRCM is growing rapidly, with estimates suggesting only 20-25,000 patients currently on therapy out of hundreds of thousands affected [17] - The company anticipates that as awareness grows, more community-based prescribers will begin to treat patients, expanding the market further [21] Upcoming Clinical Trials - BridgeBio is conducting three pivotal phase three trials with expected updates in the next 6-12 months, targeting billion-dollar market opportunities [23][24] - Infogratenin for skeletal dysplasias is projected to have a total addressable market (TAM) of $4-5 billion, with a readout expected in early 2026 [24][25] - ADH1 shows promising mid-stage clinical data with a 79% response rate in serum calcium normalization, with a readout expected later this year [26][39] Financial Management and Future Outlook - The company aims to maintain stable operational expenses while transitioning from R&D to sales and marketing as products launch [54][55] - There is a focus on leveraging existing infrastructure for new product launches, ensuring efficient patient and physician support [53] Conclusion - BridgeBio Pharma is positioned for significant growth with a robust pipeline and a strategic focus on patient impact and market expansion. The upcoming clinical trial results and market dynamics will be critical in shaping the company's future trajectory.

1Q 2025 Earnings Presentation Pearce Hammond, Vice President IR (713) 571-4684, phammond@eogresources.com Neel Panchal, Senior Director IR (713) 571-4884, npanchal@eogresources.com Capital Discipline Operational Excellence Sustainability Culture Shelby O'Connor, Manager IR (713) 571-4560, soconnor@eogresources.com Sustainable Value Creation Through Industry Cycles EOG is focused on being among the highest return and lowest cost producers, committed to strong environmental performance and playing a significa ...

Read more on the Globe and Mail's Report on Business Best Executive Awards. About Hudbay Hudbay (TSX, NYSE: HBM) is a copper-focused critical minerals company with three long-life operations and a world-class pipeline of copper growth projects in tier-one mining jurisdictions of Canada, Peru and the United States. TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. ("Hudbay" or the "Company") (TSX, NYSE: HBM) is pleased to announce that Eugene Lei, Chief Financial Officer at Hudbay, has been re ...